Sand Hill Global Advisors LLC Buys 490 Shares of Johnson & Johnson (NYSE:JNJ)

Sand Hill Global Advisors LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,101 shares of the company’s stock after purchasing an additional 490 shares during the period. Sand Hill Global Advisors LLC’s holdings in Johnson & Johnson were worth $8,851,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Trek Financial LLC raised its position in Johnson & Johnson by 53.7% during the first quarter. Trek Financial LLC now owns 7,358 shares of the company’s stock valued at $1,140,000 after purchasing an additional 2,572 shares in the last quarter. Viawealth LLC raised its position in Johnson & Johnson by 4.5% during the first quarter. Viawealth LLC now owns 2,872 shares of the company’s stock valued at $445,000 after purchasing an additional 123 shares in the last quarter. Woodard & Co. Asset Management Group Inc. ADV raised its position in Johnson & Johnson by 1.3% during the first quarter. Woodard & Co. Asset Management Group Inc. ADV now owns 17,732 shares of the company’s stock valued at $2,749,000 after purchasing an additional 231 shares in the last quarter. Koss Olinger Consulting LLC raised its position in Johnson & Johnson by 131.6% during the first quarter. Koss Olinger Consulting LLC now owns 6,757 shares of the company’s stock valued at $1,047,000 after purchasing an additional 3,840 shares in the last quarter. Finally, Prospera Financial Services Inc raised its position in Johnson & Johnson by 43.0% during the first quarter. Prospera Financial Services Inc now owns 78,273 shares of the company’s stock valued at $12,142,000 after purchasing an additional 23,549 shares in the last quarter. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on JNJ shares. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday. TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Thursday, August 31st. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Finally, Citigroup started coverage on shares of Johnson & Johnson in a report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price target for the company. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $170.65.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $160.56 on Friday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average price of $166.11 and a two-hundred day moving average price of $161.50. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The company has a market cap of $417.29 billion, a P/E ratio of 32.50, a PEG ratio of 3.42 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. During the same period last year, the business posted $2.59 EPS. The business’s revenue was up 6.3% compared to the same quarter last year. As a group, analysts anticipate that Johnson & Johnson will post 10.03 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were paid a $1.19 dividend. The ex-dividend date was Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.96%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock worth $7,928,856 in the last three months. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.